Comparative Pharmacology
Head-to-head clinical analysis: ABACAVIR DOLUTEGRAVIR LAMIVUDINE versus EMTRICITABINE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ABACAVIR DOLUTEGRAVIR LAMIVUDINE versus EMTRICITABINE.
ABACAVIR || DOLUTEGRAVIR || LAMIVUDINE vs EMTRICITABINE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Abacavir is a carbocyclic synthetic nucleoside analog guanosine reverse transcriptase inhibitor (NRTI) that inhibits HIV-1 reverse transcriptase. Dolutegravir is an HIV-1 integrase strand transfer inhibitor (INSTI) that blocks viral integration into host DNA. Lamivudine is a synthetic nucleoside analog cytosine reverse transcriptase inhibitor (NRTI) that inhibits HIV-1 reverse transcriptase.
Nucleoside reverse transcriptase inhibitor; phosphorylated to emtricitabine triphosphate which competes with endogenous deoxycytidine triphosphate and incorporates into viral DNA causing chain termination.
One tablet (600 mg abacavir, 50 mg dolutegravir, 300 mg lamivudine) orally once daily.
200 mg orally once daily, typically in combination with other antiretroviral agents.
None Documented
None Documented
Clinical Note
moderateEmtricitabine + Ribavirin
"Emtricitabine may increase the hepatotoxic activities of Ribavirin."
Clinical Note
moderateLamivudine + Emtricitabine
"The risk or severity of adverse effects can be increased when Lamivudine is combined with Emtricitabine."
Clinical Note
moderateGanciclovir + Emtricitabine
"The risk or severity of adverse effects can be increased when Ganciclovir is combined with Emtricitabine."
Clinical Note
moderateValganciclovir + Emtricitabine
Abacavir: 1.5 hr (terminal half-life ~1.5 hr, but intracellular carbovir-TP half-life ~12-20 hr supports once-daily dosing). Dolutegravir: ~14 hr (terminal half-life, clinical context: once-daily dosing due to long intracellular half-life and high potency). Lamivudine: 5-7 hr (terminal half-life, intracellular half-life of lamivudine-TP ~18-22 hr supports once-daily dosing).
Terminal elimination half-life is approximately 10 hours (range 8–12 hours) in adults with normal renal function; prolonged to >20 hours in severe renal impairment (CrCl <30 mL/min).
Abacavir: 83% renal (primarily as metabolites via alcohol dehydrogenase and glucuronidation), 16% fecal. Dolutegravir: 64% fecal (unchanged), 32% renal (minor as metabolites via UGT1A1 and CYP3A4). Lamivudine: >70% renal (unchanged via organic cation transport).
Renal: approximately 86% of the dose is excreted unchanged in urine via glomerular filtration and active tubular secretion. Biliary/fecal: minimal (<14% as unchanged drug and metabolites in feces).
Category A/B
Category C
NRTI
Antiretroviral, NRTI
"The risk or severity of adverse effects can be increased when Valganciclovir is combined with Emtricitabine."